Roche Reports the P-II (FENopta) Study Data of Fenebrutinib for Treating Relapsing Multiple Sclerosis (RMS)
Shots:
- Roche plans to highlight 48wks. data from P-II (FENopta) OLE trial assessing the safety, efficacy & PK of fenebrutinib (BTK inhibitor) to treat RMS adults (n=109, 18-55yrs.) at ECTRIMS 2024
- Patients, treated with fenebrutinib for ~1yr., showed very low disease activity & no disability progression. During OLE study, 96% were relapse-free (ARR: 0.04) without any change in disability & 99% were free of T1 gadolinium-enhancing lesions at 48wks. with 3 times more reduction in T2 lesion volume
- Additional P-III studies, FENhance 1 & 2 in RMS as well as FENtrepid in primary progressive multiple sclerosis (PPMS), are underway to evaluate the drug’s effect on disease progression. Data is anticipated by the YE’25
Ref: Roche | Image: Roche
Related News:- Roche Reports P-II Study (FENopta) Results of Fenebrutinib for the Treatment of Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
